Bladder cancer
Conditions
Interventions
Index test:Near 
probe.
It 
is 
expected 
to 
carry 
in 
tumor 
using 
German 
Karl 
stoss 
Sponsors
The Fourth Hospital of Harbin Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. The patients who have fully understood the study and voluntarily signed the written informed consent; 2. Patients with bladder tumor diagnosed by pathology and scheduled for surgical treatment; 3. Patients aged 18-70 years old, regardless of gender; 4. Those with KPS score >= 60; 5. The patients with normal organ function (without continuous support treatment, the laboratory examination results within one week before admission); neutrophils > 1.5 x 10^9 / L, platelets > 100 x 10^9 / L, hemoglobin > 9.0g/dl; normal or < 1.5 x ULN bilirubin; ast (SGOT), ALT (SGPT) < 2.5 x ULN (if liver metastasis, < 5 x ULN); serum creatinine < 1.5 x ULN; 6. Patients with an estimated survival time of 3 months or more.
Exclusion criteria
Exclusion criteria: 1. Patients with cystitis; 2. Patients with urinary system malformation or urethral stricture; 3. Patients with white blood cell count less than 1.5 x 10^9 / L or neutrophil count less than 1.0 x 10^9 / L; 4. Pregnant or lactating subjects; 5. Patients with other serious systemic diseases; 6. Patients who are allergic to a variety of drugs; 7. Those who are participating in or have participated in another clinical study within the last 30 days; 8. It is estimated that the compliance of patients participating in this clinical study is insufficient.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fluorescence intensity of bladder tumor; | — |
Countries
China
Contacts
Public ContactWanhai Xu
The Fourth Affiliated Hospital of Harbin Medical University
Outcome results
None listed